Lofat 200

Indications

Lofat is prescribed for managing types IIA, IIB, III, IV, and V hyperlipidemias in patients who have not responded adequately to diet and other treatments.

Pharmacology

Fenofibrate, a derivative of fibric acid, undergoes rapid hydrolysis post oral ingestion to fenofibric acid, its active form. Fenofibric acid effectively reduces total cholesterol, LDL cholesterol, Apo-lipoprotein B, total triglycerides, and VLDL levels. Moreover, treatment with Fenofibrate enhances HDL levels and apo-proteins apoAI and apoAII. It also lowers serum uric acid by increasing its urinary excretion. Micronised Nofiate (Fenofibrate) exhibits improved absorption compared to non-micronised formulations.

Dosage & Administration

For adults with hypercholesterolemia or mixed hyperlipidemia, the initial dose of Fenofibrate is typically 200 mg daily. For hypertriglyceridemia, the initial dose ranges from 67 to 200 mg per day. Dosage adjustments should be made based on individual patient response. Fenofibrate should be taken with meals to optimize bioavailability, or as directed by a healthcare provider.

Interactions

Lofat may potentiate the anticoagulant effects of warfarin and improve glucose tolerance when used with antidiabetic drugs. It can increase the nephrotoxicity of cyclosporine and caution is advised when co-administered with HMG-CoA reductase inhibitors due to potential risks of rhabdomyolysis, although low-dose statins appear to be well tolerated.

Contraindications

Fenofibrate should not be used in patients with hypersensitivity to Fenofibrate, severe renal or hepatic impairment, existing gall bladder disease, breastfeeding mothers, or those with photosensitivity to ketoprofen.

Side Effects

Common side effects include gastrointestinal discomfort (e.g., nausea, anorexia, gastric pain), pruritus, urticaria, impotence, as well as headache, dizziness, vertigo, fatigue, and hair loss. Myotoxicity has also been reported.

Pregnancy & Lactation

Fenofibrate is not recommended for use during pregnancy due to potential risks.

Precautions & Warnings

Special care is necessary in patients with renal disease, as improper dosage may lead to myotoxicity. Liver function tests should be conducted every three months during the first year of treatment.

Overdose Effects

No specific antidote is available for Lofat overdose. Supportive care, including monitoring vital signs and clinical status, is recommended. Hemodialysis is not effective due to Lofat’s high plasma protein binding.

Therapeutic Class

Fibrates

Storage Conditions

Store below 30°C, protect from light, and keep out of reach of children.